Receive regular headline summaries whenever high-quality news is generated for this page. We'll never share your email address with others.
|4/13/2022||Versant-backed startup launches with plans to broaden cell therapy's reach
... least some of these problems can be overcome. Called Cimeio Therapeutics , the new company is led by a team of pharmaceutical industry veterans and an advisory board filled with scientific luminaries, including immunologist Jeffrey Bluestone and gene editing pioneer Fyodor Urnov. Cimeio's approach involves "shielding" transplanted cells by genetically editing ...
|9/16/2021||Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary
... team to help guide the strategic business decisions of the company. ‚ÄúWe are delighted to welcome Doug to the team as we continue this period of rapid growth as a company,‚Äù said Jeffrey Bluestone, Ph.D., Co-founder and CEO of Sonoma Biotherapeutics. ‚ÄúHis decades of biopharma legal experience will ...
|8/4/2021||Sonoma Bio bags $265M to rev up cell therapies for arthritis, diabetes
... for autoimmune diseases, including Type 1 diabetes and rheumatoid arthritis. Its cell therapies are based on regulatory T cells, or Tregs, which identify unwanted inflammatory and autoimmune responses and shut them down, said Jeffrey Bluestone, Ph.D., CEO and co-founder of Sonoma Bio. Since its launch, the company has added ...
|2/6/2020||Sonoma Bio debuts with $40M to push Treg treatments for autoimmune, neuro diseases||FierceBiotech|
|2/6/2020||Sonoma Biotherapeutics Launches With $40 Million In Series A Funding To Advance Regulatory T Cell Therapy In Autoimmune And Degenerative Diseases - TheStreet||TheStreet|
|2/6/2020||Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases||STAT|
|1/14/2020||Opinion: Innovation in biotech R&D: New resources offer new hope||STAT|
|5/10/2019||The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research||ascopost.com|
|5/10/2019||How the Nobel Prize Could Spur More Cancer Advances||ascopost.com|
|5/10/2019||Advancing Immune Checkpoint Targeting in Cancer Treatment||ascopost.com|
|10/31/2017||BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies||PR Newswire|
|10/31/2017||BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials||PR Newswire|